Keyphrases
Recent Advances
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Nab-paclitaxel
100%
Taxanes
100%
Solvent-based Paclitaxel
71%
Carboplatin
42%
Pemetrexed
42%
Overall Response Rate
28%
Maintenance Therapy
28%
Non-small Cell Lung Cancer (NSCLC)
28%
Cisplatin
28%
Subset Analysis
28%
Non-squamous Non-small Cell Lung Cancer
28%
Treatment Options
14%
Tumor
14%
Overall Survival
14%
Gemcitabine
14%
Hearing Impairment
14%
Phase II Trial
14%
Albumin
14%
Daily Living
14%
Non-small Cell Lung Cancer Patients
14%
Neuropathy
14%
Squamous Histology
14%
Bevacizumab
14%
Toxicity Issues
14%
Frontline Treatment
14%
Survival Median
14%
Nonsquamous Histology
14%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Paclitaxel
100%
Taxane
100%
Carboplatin
25%
Pemetrexed
25%
Cisplatin
16%
Neoplasm
8%
Overall Survival
8%
Hearing Impairment
8%
Neuropathy
8%
Bevacizumab
8%
Gemcitabine
8%